Peritoneal dialysis: A biological membrane with a nonbiological fluid

Contributions to Nephrology

Volumn 163, Issue , 2009, Pages 27-34

  Witowski, Janusz ^a,b   Jörres, Achim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; CELL AGING; CHRONIC DISEASE; DISEASE MODEL; EPITHELIUM; FIBROSIS; HUMAN; KIDNEY DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEUM; PHYSIOLOGY; RAT; VASCULARIZATION;

ANIMALS; CELL AGING; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; EPITHELIUM; FIBROSIS; HUMANS; KIDNEY DISEASES; PERITONEAL DIALYSIS; PERITONEUM; RATS;

EID: 67651219135     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000223777     Document Type: Article

References (60)

1. Slingeneyer A, Canaud B, Mion C: Permanent loss of ultrafi ltration capacity of the peritoneum in long-term peritoneal dialysis: an epidemiological study. Nephron 1983;33:133-138.
2. Ho-Dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT: Analysis of ultrafi ltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997;17:144-150.
3. Heimburger O, Waniewski J, Werynski A, et al: Peritoneal transport in CAPD patients with permanent loss of ultrafi ltration capacity. Kidney Int 1990;38:495-506.
4. Margetts PJ, Churchill DN: Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 2002;13:2787-2794.
5. Williams JD, Craig KJ, Topley N, et al: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
6. Wieslander A P, Kjellstrand PT, Rippe B: Heat sterilization of glucose-containing fl uids for peritoneal dialysis: biological consequences of chemical alterations. Perit Dial Int 1995;15:S52-S59.
7. Witowski J, Jörres A: Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Perit Dial Int 2005;25(suppl 3):S31-S34.
8. Morgan LW, Wieslander A, Davies M, et al: Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003;64:1854-1866.
9. Witowski J, Korybalska K, Wisniewska J, et al: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000;11:729-739.
10. Lamb EJ, Cattell WR, Dawnay AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995;47:1768-1774.
11. Tauer A, Knerr T, Niwa T, et al: In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001;280:1408-1414.
12. Nakayama M, Kawaguchi Y, Yamada K, et al: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
13. Honda K, Nitta K, Horita S, et al: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999;14:1541-1549.
14. Witowski J, Wisniewska J, Korybalska K, et al: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434-2441.
15. Santamaria B, Ucero AC, Reyero A, et al: 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization. Nephrol Dial Transplant 2008;23:3307-3315.
16. Tomo T, Okabe E, Yamamoto T, et al: Synergistic cytotoxicity of acidity and 3,4-dideoxyglucosone-3-ene under the existence of lactate in peritoneal dialysis fluid. Ther Apher Dial 2005;9:182-187.
17. Alhamdani MS, Al Kassir AH, Abbas FK, et al: Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron Clin Pract 2007;107:c26-c34.
18. Leung JC, Chan LY, Li FF, et al: Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. Nephrol Dial Transplant 2005;20:1336- 1349.
19. Breborowicz A, Witowski J, Polubinska A, et al: L-2-Oxothiazolidine-4- carboxylic acid reduces in vitro cytotoxicity of glucose degradation products. Nephrol Dial Transplant 2004;19:3005-3011.
20. Yamamoto T, Tomo T, Okabe E, et al: Glutathione depletion as a mechanism of 3,4-dideoxyglucosone-3-ene-induced cytotoxicity in human peritoneal mesothelial cells: role in biocompatibility of peritoneal dialysis fl uids. Nephrol Dial Transplant 2009;4:1436-1442.
21. Boulanger E, Wautier M P, Gane P, et al: The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004;19:2208-2216.
22. Welten AG, Schalkwijk CG, ter Wee PM, et al: Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proin-flammatory response. Perit Dial Int 2003;23:213-221.
23. Witowski J, Jörres A, Korybalska K, et al: Glucose degradation products in peritoneal dialysis fluids: do they harm? Kidney Int 2003;(suppl):S148-S151.
24. Lee DH, Choi SY, Ryu HM, et al: 3,4-Dideoxyglucosone-3-ene induces apoptosis in human peritoneal mesothelial cells. Perit Dial Int 2009;29:44-51.
25. Lai KN, Leung JC, Chan LY, et al: Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004;138:466-475.
26. Inagi R, Miyata T, Yamamoto T, et al: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999;463:260- 264.
27. Korybalska K, Wisniewska-Elnur J, Trominska J, et al: The role of the glyoxalase pathway in reducing mesothelial toxicity of glucose degradation products. Perit Dial Int 2006;26:259-265.
28. Pajek J, Kveder R, Bren A, et al: Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fl uid on peritoneal and systemic infl ammation in CAPD patients: a randomized controlled study. Perit Dial Int 2008;28:44-52.
29. Hirahara I, Ishibashi Y, Kaname S, et al: Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant 2009;24:437-447.
30. Locatelli F, La MV: Preservation of residual renal function in peritoneal dialysis patients: still a dream? Kidney Int 2008;73:143-145.
31. Krediet RT: Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001;21:560-567.
32. Jones S, Holmes CJ, Krediet RT, et al: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001;59:1529- 1538.
33. Fusshoeller A, Plail M, Grabensee B, Plum J: Biocompatibility pattern of a bicarbonate/lactatebuffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004;19:2101-2106.
34. Rippe B, Simonsen O, Heimburger O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
35. Williams JD, Topley N, Craig KJ, et al: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
36. Szeto CC, Chow KM, Lam C W, et al: Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007;22:552-559.
37. Choi HY, Kim DK, Lee TH, et al: The clinical usefulness of peritoneal dialysis fl uids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008;28:174-182.
38. Haas S, Schmitt CP, Arbeiter K, et al: Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003;14:2632-2638.
39. Topley N, Michael D, Bowen T: CA125: holy grail or a poisoned chalice. Nephron Clin Pract 2005;100:c52-c54.
40. Breborowicz A, Breborowicz M, Pyda M, et al: Limitations of CA125 as an index of peritoneal mesothelial cell mass. Nephron Clin Pract 2005;100:c46-c51.
41. Aroeira LS, Aguilera A, Sanchez-Tomero JA, et al: Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic signifi cance and potential therapeutic interventions. J Am Soc Nephrol 2007;18:2004-2013.
42. Yanez-Mo M, Lara-Pezzi E, Selgas R, et al: Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003;348:403-413.
43. Jimenez-Heffernan JA, Aguilera A, Aroeira LS, et al: Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fi brosis. Virchows Arch 2004;444:247-256.
44. Zavadil J, Bottinger EP: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-5774.
45. Yang AH, Chen JY, Lin JK: Myofi broblastic conversion of mesothelial cells. Kidney Int 2003;63:1530-1539.
46. Margetts PJ, Bonniaud P, Liu L, et al: Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005;16:425-436.
47. Zhang J, Oh KH, Xu H, Margetts PJ: Vascular endothelial growth factor expression in peritoneal mesothelial cells undergoing transdifferentiation. Perit Dial Int 2008;28:497-504.
48. Aroeira LS, Aguilera A, Selgas R, et al: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005;46:938-948.
49. Aroeira LS, Lara-Pezzi E, Loureiro J, et al: Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J Am Soc Nephrol 2009;20:582-592.
50. Do JY, Kim YL, Park J W, et al: The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit Dial Int 2008;28(suppl 3):S101-S106.
51. Yu MA, Shin KS, Kim JH, et al: HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol 2009;20:567-581.
52. Gotloib L, Shostak A, Wajsbrot V, Kushnier R: High glucose induces a hypertrophic, senescent mesothelial cell phenotype after long in vivo exposure. Nephron 1999;82:164-173.
53. Gotloib L, Wajsbrot V, Shostak A: Icodextrin-induced lipid peroxidation disrupts the mesothelial cell cycle engine. Free Radic Biol Med 2003;34:419-428.
54. Witowski J, Ksiazek K, Jörres A: Glucose-induced mesothelial cell senescence and peritoneal neoangiogenesis and fibrosis. Perit Dial Int 2008;28(suppl 5):S34-S37.
55. Ksiazek K, Piwocka K, Brzezinska A, et al: Early loss of proliferative potential of human peritoneal mesothelial cells in culture: the role of p16INK4a-mediated premature senescence. J Appl Physiol 2006;100:988-995.
56. Ksiazek K, Korybalska K, Jörres A, Witowski J: Accelerated senescence of human peritoneal mesothelial cells exposed to high glucose: the role of TGF-beta1. Lab Invest 2007;87:345-356.
57. Ksiazek K, Jörres A, Witowski J: Senescence induces a proangiogenic switch in human peritoneal mesothelial cells. Rejuvenation Res 2008;11:681-683.
58. Ksiazek K, Passos JF, Olijslagers S, et al: Premature senescence of mesothelial cells is associated with non-telomeric DNA damage. Biochem Biophys Res Commun 2007;362:707-711.
59. Ksiazek K, Passos JF, Olijslagers S, von Zglinicki T: Mitochondrial dysfunction is a possible cause of accelerated senescence of mesothelial cells exposed to high glucose. Biochem Biophys Res Commun 2008;366:793-799.
60. Ksiazek K, Breborowicz A, Jörres A, Witowski J: Oxidative stress contributes to accelerated development of the senescent phenotype in human peritoneal mesothelial cells exposed to high glucose. Free Radic Biol Med 2007;42:636-641.